Tesseract Medicines develops targeted therapeutics described in the article as "covalent induced conjugate" drugs designed to deliver cytotoxic payloads precisely to cancer-relevant intracellular proteins. The company is primarily engaged in R&D of these targeted delivery drugs. Its platform aims to achieve selective intracellular targeting of cancer-specific proteins to improve therapeutic index. The article reports the company completed a financing event, indicating early-stage commercial funding activity to support development. No revenue or user metrics are provided in the article. The report does not state a founding year or headquarters location. Public disclosure about further clinical or commercial plans beyond R&D was not included in the article.

Total raised

$20M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2024